Ontology highlight
ABSTRACT: Purpose
The aim of this work was to develop a CAIX-specific nanobody conjugated to IRDye800CW for molecular imaging of pre-invasive breast cancer.Procedures
CAIX-specific nanobodies were selected using a modified phage display technology, conjugated site-specifically to IRDye800CW and evaluated in a xenograft breast cancer mouse model using ductal carcinoma in situ cells (DCIS).Results
Specific anti-CAIX nanobodies were obtained. Administration of a CAIX-specific nanobody into mice with DCIS xenografts overexpressing CAIX showed after 2 h a mean tumor-to-normal tissue ratio (TNR) of 4.3?±?0.6, compared to a TNR of 1.4?±?0.2 in mice injected with the negative control nanobody R2-IR. In DCIS mice, a TNR of 1.8?±?0.1 was obtained. Biodistribution studies demonstrated an uptake of 14.0?±?1.1 %I.D./g in DCIS?+?CAIX tumors, 4.6?±?0.8 %I.D./g in DCIS tumors, while 2.0?±?0.2 %I.D./g was obtained with R2-IR.Conclusions
These results demonstrate the successful generation of a CAIX-specific nanobody-IRDye800CW conjugate that can be used for rapid imaging of (pre-)invasive breast cancer.
SUBMITTER: van Brussel AS
PROVIDER: S-EPMC4927611 | biostudies-literature | 2016 Aug
REPOSITORIES: biostudies-literature
van Brussel Aram S A AS Adams Arthur A Oliveira Sabrina S Dorresteijn Bram B El Khattabi Mohamed M Vermeulen Jeroen F JF van der Wall Elsken E Mali Willem P Th M WP Derksen Patrick W B PW van Diest Paul J PJ van Bergen En Henegouwen Paul M P PM
Molecular imaging and biology 20160801 4
<h4>Purpose</h4>The aim of this work was to develop a CAIX-specific nanobody conjugated to IRDye800CW for molecular imaging of pre-invasive breast cancer.<h4>Procedures</h4>CAIX-specific nanobodies were selected using a modified phage display technology, conjugated site-specifically to IRDye800CW and evaluated in a xenograft breast cancer mouse model using ductal carcinoma in situ cells (DCIS).<h4>Results</h4>Specific anti-CAIX nanobodies were obtained. Administration of a CAIX-specific nanobody ...[more]